Novo Nordisk A/S is a Danish multinational pharmaceutical company focused on therapies for diabetes, obesity, and rare endocrine and hematology disorders. Founded in 1923 and headquartered in Bagsværd, Denmark, the company develops and manufactures peptide and protein-based medicines, including insulin and GLP‑1 analogues, as well as treatments for hemophilia and growth disorders.
For the chemical and life sciences value chain, Novo Nordisk operates integrated R&D, API production, and fill‑finish facilities across Europe, North America, and Asia. Its manufacturing capabilities span recombinant protein expression, peptide synthesis, formulation science, device-engineering for injection systems, and sterile aseptic processing. The company’s activities connect upstream biochemical and chemical process development with large-scale biologics and injectable drug production, supported by quality, regulatory, and supply chain operations serving global healthcare markets.